|
|
 Previous Article | Table of Contents | Next Article 
Expression of human B cell-associated antigens on leukemias and lymphomas:
a model of human B cell differentiation
KC Anderson, MP Bates, BL Slaughenhoupt, GS Pinkus, SF Schlossman and LM Nadler
A series of monoclonal antibodies that define B cell restricted and
associated antigens was utilized in an attempt to characterize tumors of B
lineage and to relate these tumors to B cell differentiative stages.
Antigens that were previously shown to be B cell restricted on normal B
lymphocytes were similarly expressed only on B cell malignancies. In
contrast, antigens that were B cell associated were also found on tumors of
other lineages. Moreover, on the basis of cell surface phenotypes, tumors
of B cell origin were divided into three major subgroups, which
corresponded to the level of differentiation of the malignant tumor cell:
pre-B cell stage (non-T acute lymphoblastic leukemia and chronic myelocytic
leukemia in lymphoid blast crisis); the mid-B cell stage (chronic
lymphocytic leukemia, poorly differentiated lymphomas); and secretory B
cell stage (large cell lymphomas and plasma cell tumors). A hypothetical
model is derived that relates the malignant B cell to its normal cellular
counterpart on the basis of cell surface expression of this panel of B
cell-restricted and B cell- associated antigens.
Volume 63,
Issue 6,
pp. 1424-1433,
06/01/1984
Copyright © 1984 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Zalevsky, I. W. L. Leung, S. Karki, S. Y. Chu, E. A. Zhukovsky, J. R. Desjarlais, D. F. Carmichael, and C. E. Lawrence
The impact of Fc engineering on an anti-CD19 antibody: increased Fc{gamma} receptor affinity enhances B-cell clearing in nonhuman primates
Blood,
April 16, 2009;
113(16):
3735 - 3743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Horton, M. J. Bernett, E. Pong, M. Peipp, S. Karki, S. Y. Chu, J. O. Richards, I. Vostiar, P. F. Joyce, R. Repp, et al.
Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
Cancer Res.,
October 1, 2008;
68(19):
8049 - 8057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhou, W. Hu, and X. Qin
The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
Oncologist,
September 1, 2008;
13(9):
954 - 966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV
Blood,
August 15, 2008;
112(4):
1205 - 1213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. James, P. D. Greenberg, M. C. Jensen, Y. Lin, J. Wang, B. G. Till, A. A. Raubitschek, S. J. Forman, and O. W. Press
Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane
J. Immunol.,
May 15, 2008;
180(10):
7028 - 7038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Isenberg
Treating patients with lupus with B-cell depletion
Lupus,
May 1, 2008;
17(5):
400 - 404.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, M. Tani, S. Fanti, V. Stefoni, G. Musuraca, P. Castellucci, E. Marchi, M. Farsad, M. Fina, C. Pellegrini, et al.
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
Ann. Onc.,
April 1, 2008;
19(4):
769 - 773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
J. Nucl. Med.,
November 1, 2007;
48(11):
1767 - 1776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Leonard, B. K. Link, C. Emmanouilides, S. A. Gregory, D. Weisdorf, J. Andrey, J. Hainsworth, J. A. Sparano, D. E. Tsai, S. Horning, et al.
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non Hodgkin's Lymphoma
Clin. Cancer Res.,
October 15, 2007;
13(20):
6168 - 6174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Cooney-Qualter, M. Krailo, A. Angiolillo, R. A. Fawwaz, G. Wiseman, L. Harrison, V. Kohl, P. C. Adamson, J. Ayello, C. vande Ven, et al.
A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non Hodgkin's Lymphoma: A Children's Oncology Group Study
Clin. Cancer Res.,
September 15, 2007;
13(18):
5652s - 5660s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, T. Illidge, D. Huglo, G. Martinelli, G. Paganelli, P. L. Zinzani, S. Rule, A. M. Liberati, N. Milpied, G. Hess, et al.
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation
Blood,
July 1, 2007;
110(1):
54 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Du, H. Wang, C. Zhong, B. Peng, M. Zhang, B. Li, S. Huo, Y. Guo, and J. Ding
Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab
J. Biol. Chem.,
May 18, 2007;
282(20):
15073 - 15080.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nomura, K. Ishii, Y. Kamitsuji, N. Uoshima, E. Ishikawa, H. Kitayama, and K. Hayashi
Elevation of Activated Platelet-Dependent Chemokines in Patients With Anti-CD20 Monoclonal Antibody (Rituximab)-Treated Non-Hodgkin's Lymphoma
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2007;
13(2):
206 - 212.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Lepelletier, V. Camara-Clayette, H. Jin, A. Hermant, S. Coulon, M. Dussiot, M. Arcos-Fajardo, C. Baude, D. Canionni, R. Delarue, et al.
Prevention of Mantle Lymphoma Tumor Establishment by Routing Transferrin Receptor toward Lysosomal Compartments
Cancer Res.,
February 1, 2007;
67(3):
1145 - 1154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Jazirehi, M. I. Vega, and B. Bonavida
Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy
Cancer Res.,
February 1, 2007;
67(3):
1270 - 1281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Khan, C. Emmanouilides, D. M. Benson Jr., D. Hurst, P. Garcia, G. Michelson, S. Milan, A. K. Ferketich, L. Piro, J. P. Leonard, et al.
A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
December 1, 2006;
12(23):
7046 - 7053.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Serrano, T. Pfeiffer, S. Olivares, T. Numbenjapon, J. Bennitt, D. Kim, D. Smith, G. McNamara, Z. Al-Kadhimi, J. Rosenthal, et al.
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy
Blood,
April 1, 2006;
107(7):
2643 - 2652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Perosa, E. Favoino, M. A. Caragnano, and F. Dammacco
Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor
Blood,
February 1, 2006;
107(3):
1070 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Greenberg, E. M. Bradshaw, J. L. Pinkus, G. S. Pinkus, T. Burleson, B. Due, L. S. Bregoli, K. C. O'Connor, and A. A. Amato
Plasma cells in muscle in inclusion body myositis and polymyositis
Neurology,
December 13, 2005;
65(11):
1782 - 1787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Kaminski, J. A. Radford, S. A. Gregory, J. P. Leonard, S. J. Knox, S. Kroll, and R. L. Wahl
Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab
J. Clin. Oncol.,
November 1, 2005;
23(31):
7985 - 7993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Vallera, M. W. Brechbiel, L. J. Burns, A. Panoskaltsis-Mortari, K. E. Dusenbery, D. R. Clohisy, and E. S. Vitetta
Radioimmunotherapy of CD22-Expressing Daudi Tumors in Nude Mice with a 90Y-Labeled Anti-CD22 Monoclonal Antibody
Clin. Cancer Res.,
November 1, 2005;
11(21):
7920 - 7928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Fisher, M. S. Kaminski, R. L. Wahl, S. J. Knox, A. D. Zelenetz, J. M. Vose, J. P. Leonard, S. Kroll, S. J. Goldsmith, and M. Coleman
Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphomas
J. Clin. Oncol.,
October 20, 2005;
23(30):
7565 - 7573.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Yazawa, Y. Hamaguchi, J. C. Poe, and T. F. Tedder
Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease
PNAS,
October 18, 2005;
102(42):
15178 - 15183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado
Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms
J. Immunol.,
June 15, 2005;
174(12):
7859 - 7868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Vallera, D. A. Todhunter, D. W. Kuroki, Y. Shu, A. Sicheneder, and H. Chen
A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma
Clin. Cancer Res.,
May 15, 2005;
11(10):
3879 - 3888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas, D. Podoloff, and M. Goris
Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab
J. Clin. Oncol.,
February 1, 2005;
23(4):
712 - 719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Forstpointner, M. Dreyling, R. Repp, S. Hermann, A. Hanel, B. Metzner, C. Pott, F. Hartmann, F. Rothmann, R. Rohrberg, et al.
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Blood,
November 15, 2004;
104(10):
3064 - 3071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Brugger, J. Hirsch, F. Grunebach, R. Repp, P. Brossart, W. Vogel, H.-G. Kopp, M. G. Manz, M. Bitzer, G. Schlimok, et al.
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study
Ann. Onc.,
November 1, 2004;
15(11):
1691 - 1698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Lang, K. Barbin, T. Feuchtinger, J. Greil, M. Peipp, S. J. Zunino, M. Pfeiffer, R. Handgretinger, D. Niethammer, and G. H. Fey
Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts
Blood,
May 15, 2004;
103(10):
3982 - 3985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.J. Davies, A.Z.S. Rohatiner, S. Howell, K.E. Britton, S.E. Owens, I.N. Micallef, D.P. Deakin, B.M. Carrington, J.A. Lawrance, S. Vinnicombe, et al.
Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
April 15, 2004;
22(8):
1469 - 1479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. L. Gluck, D. Hurst, A. Yuen, A. M. Levine, M. A. Dayton, J. P. Gockerman, J. Lucas, K. Denis-Mize, B. Tong, D. Navis, et al.
Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin's Lymphoma: IL-2 Mediated Natural Killer Cell Expansion Correlations with Clinical Response
Clin. Cancer Res.,
April 1, 2004;
10(7):
2253 - 2264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Uchida, Y. Lee, M. Hasegawa, Y. Liang, A. Bradney, J. A. Oliver, K. Bowen, D. A. Steeber, K. M. Haas, J. C. Poe, et al.
Mouse CD20 expression and function
Int. Immunol.,
January 1, 2004;
16(1):
119 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Jilani, S. O'Brien, T. Manshuri, D. A. Thomas, V. A. Thomazy, M. Imam, S. Naeem, S. Verstovsek, H. Kantarjian, F. Giles, et al.
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
Blood,
November 15, 2003;
102(10):
3514 - 3520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Fink-Bennett and K. Thomas
90Y-Ibritumomab Tiuxetan in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
J. Nucl. Med. Technol.,
June 1, 2003;
31(2):
61 - 68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Manches, G. Lui, L. Chaperot, R. Gressin, J.-P. Molens, M.-C. Jacob, J.-J. Sotto, D. Leroux, J.-C. Bensa, and J. Plumas
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Blood,
February 1, 2003;
101(3):
949 - 954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. D. Davis, M. Jefford, P. Parente, and J. Cebon
Rational approaches to human cancer immunotherapy
J. Leukoc. Biol.,
January 1, 2003;
73(1):
3 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Lowndes, A. Darby, G. Mead, and A. Lister
Stevens-Johnson syndrome after treatment with rituximab
Ann. Onc.,
December 1, 2002;
13(12):
1948 - 1950.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Ansell, K. M. Ristow, T. M. Habermann, G. A. Wiseman, and T. E. Witzig
Subsequent Chemotherapy Regimens Are Well Tolerated After Radioimmunotherapy With Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
September 15, 2002;
20(18):
3885 - 3890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Dimopoulos, C. Zervas, A. Zomas, C. Kiamouris, N. A. Viniou, V. Grigoraki, C. Karkantaris, C. Mitsouli, D. Gika, J. Christakis, et al.
Treatment of Waldenstrom's Macroglobulinemia With Rituximab
J. Clin. Oncol.,
May 1, 2002;
20(9):
2327 - 2333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. Howard, J. G. Gribben, D. S. Neuberg, M. Grossbard, C. Poor, M. J. Janicek, and M. A. Shipp
Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival
J. Clin. Oncol.,
March 1, 2002;
20(5):
1288 - 1294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Vose, B. C.-H. Chiu, B. D. Cheson, J. Dancey, and J. Wright
Update on Epidemiology and Therapeutics for Non-Hodgkin's Lymphoma
Hematology,
January 1, 2002;
2002(1):
241 - 262.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. M. Ansell, T. E. Witzig, P. J. Kurtin, J. A. Sloan, D. F. Jelinek, K. G. Howell, S. N. Markovic, T. M. Habermann, G. G. Klee, P. J. Atherton, et al.
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
Blood,
January 1, 2002;
99(1):
67 - 74.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Husson, E. G. Carideo, D. Neuberg, J. Schultze, O. Munoz, P. W. Marks, J. W. Donovan, A. C. Chillemi, P. O'Connell, and A. S. Freedman
Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays
Blood,
January 1, 2002;
99(1):
282 - 289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-K. Weng and R. Levy
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
Blood,
September 1, 2001;
98(5):
1352 - 1357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Mathas, A. Rickers, K. Bommert, B. Dörken, and M. Y. Mapara
Anti-CD20- and B-cell Receptor-mediated Apoptosis: Evidence for Shared Intracellular Signaling Pathways
Cancer Res.,
December 1, 2000;
60(24):
7170 - 7176.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. A. Davis, A. J. Grillo-Lopez, C. A. White, P. McLaughlin, M. S. Czuczman, B. K. Link, D. G. Maloney, R. L. Weaver, J. Rosenberg, and R. Levy
Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment
J. Clin. Oncol.,
September 17, 2000;
18(17):
3135 - 3143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kunkel and T. A. Davis
Correspondence re: T. Davis et al., Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in Loss of CD20 Antigen Expression. Clin. Cancer Res., 5: 611-615, 1999.
Clin. Cancer Res.,
January 1, 2000;
6(1):
317 - 318.
[Full Text]
|
|
|
|
|
|
|
T. D. Levine and A. Pestronk
IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab
Neurology,
May 1, 1999;
52(8):
1701 - 1701.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. S. Czuczman, A. J. Grillo-Lopez, C. A. White, M. Saleh, L. Gordon, A. F. LoBuglio, C. Jonas, D. Klippenstein, B. Dallaire, and C. Varns
Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
J. Clin. Oncol.,
January 1, 1999;
17(1):
268 - 268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Davis, D. G. Maloney, D. K. Czerwinski, T.-M. Liles, and R. Levy
Anti-Idiotype Antibodies Can Induce Long-Term Complete Remissions in Non-Hodgkin's Lymphoma Without Eradicating the Malignant Clone
Blood,
August 15, 1998;
92(4):
1184 - 1190.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney, A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T.-M. Liles, B. K. Dallaire, et al.
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Blood,
September 15, 1997;
90(6):
2188 - 2195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-C. Goulet, V. S. Goldmacher, J. M. Lambert, C. Baron, D.-C. Roy, and E. Kouassi
Conjugation of Blocked Ricin to an Anti-CD19 Monoclonal Antibody Increases Antibody-Induced Cell Calcium Mobilization and CD19 Internalization
Blood,
September 15, 1997;
90(6):
2364 - 2375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Greaves
Differentiation-linked leukemogenesis in lymphocytes
Science,
November 7, 1986;
234(4777):
697 - 704.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. C. ANDERSON, B. C. GORGONE, R. G. MARLINK, R. FERRIANI, M. E. ESSEX, P. M. BENZ, and J. E. GROOPMAN
Transfusion-Acquired Human Immunodeficiency Virus Infection Among Immunocompromised Persons
Ann Intern Med,
October 1, 1986;
105(4):
519 - 527.
[Abstract]
[PDF]
|
|
|
|
|
